Current Report Filing (8-k)
August 12 2021 - 8:04AM
Edgar (US Regulatory)
0001346830
false
0001346830
2021-08-12
2021-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported) August 12, 2021
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-36279
|
|
75-3175693
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
4 Stamford
Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut
|
|
|
|
06902
|
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant's telephone number, including area code (203) 406-3700
|
|
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2.):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
CARA
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨.
|
Item 7.01.
|
Regulation FD Disclosure.
|
On August 12, 2021, Cara Therapeutics, Inc. (the “Company”)
made available an updated corporate presentation that the Company may utilize from time to time in connection with investor meetings,
which can be found on the Company’s website (the “Corporate Presentation”). The Corporate Presentation is furnished
as Exhibit 99.1 and incorporated by reference in this Item 7.01.
The information furnished under this Item 7.01, including Exhibit 99.1,
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject
to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities
and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CARA THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ THOMAS REILLY
|
|
|
|
Thomas Reilly
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Financial and Accounting Officer)
|
Date: August 12, 2021
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024
